Trepanier Angela M, Aguilar Sienna, Kamholz John, Laukka Jeremy J
Center for Molecular Medicine and Genetics Wayne State University School of Medicine Detroit Michigan USA.
Invitae, Inc. San Francisco California USA.
Clin Case Rep. 2023 Aug 25;11(9):e7814. doi: 10.1002/ccr3.7814. eCollection 2023 Sep.
This study aimed to characterize the clinical features, developmental milestones, and the natural history of Pelizaeus-Merzbacher disease (PMD) associated with gene duplications. The study examined 16 PMD Patients ranging in age from 7 to 48 years, who had a documented gene duplication. The study examined and analyzed the medical and developmental histories of the subjects utilizing a combination of resources that included medical history questionnaires, medical record reviews, and a 31-point functional disability scale that had been previously validated. The data extracted from the medical records and questionnaires for analysis included information related to medical and developmental histories, level of ambulation and cognition, and degree of functional disability. The summation of findings among the study population demonstrated that the presenting symptoms, developmental milestones achieved, and progression of symptoms reported are consistent with many previous studies of patients with duplications. All patients exhibited onset within the first year of life, with nystagmus predominating as the first symptom noticed. All patients exhibited delays in both motor and language development; however, many individuals were able to meet several developmental milestones. They exhibited some degree of continued motor impairment with none having the ability to walk independently. All patients were able to complete at least some of the cognition achievements and although not all were verbal, a number were able to use communication devices to complete these tasks. A critical tool of the study was the functional disability scale which provided a major advantage in helping quantify the clinical course of PMD, and for several, we were able to gather this information at more than one point in time. These reported findings in our cohort contribute important insight into the clinical heterogeneity and potential underlying mechanisms that define the molecular pathogenesis of the disease. This is one of only a small number of natural history studies examining the clinical course of a cohort of patients with duplications within the context of a validated functional disability scoring system. This study is unique in that it is limited to subjects with gene duplications. This study demonstrated many commonalities to other studies that have characterized the features of PMD and other PLP1-related disorders but also provide significant new insights into the evolving story that marks the natural history.
本研究旨在描述与基因重复相关的佩利措伊斯-梅茨巴赫病(PMD)的临床特征、发育里程碑及自然病史。该研究对16例年龄在7至48岁之间、有记录的基因重复的PMD患者进行了检查。研究利用包括病史问卷、病历审查以及先前已验证的31分功能残疾量表在内的多种资源,对受试者的医学和发育史进行了检查与分析。从病历和问卷中提取用于分析的数据包括与医学和发育史、行走和认知水平以及功能残疾程度相关的信息。研究人群的研究结果总结表明,所呈现的症状、达到的发育里程碑以及报告的症状进展与先前许多关于基因重复患者的研究一致。所有患者均在出生后第一年内发病,眼球震颤是最早被注意到的症状。所有患者在运动和语言发育方面均有延迟;然而,许多个体能够达到几个发育里程碑。他们表现出一定程度的持续性运动障碍,无人能够独立行走。所有患者至少能够完成一些认知成就,尽管并非所有人都能言语,但有一些人能够使用通讯设备完成这些任务。该研究的一个关键工具是功能残疾量表,它在帮助量化PMD的临床病程方面具有主要优势,对于其中一些患者,我们能够在多个时间点收集这些信息。我们队列中的这些报告结果为定义该疾病分子发病机制的临床异质性和潜在潜在机制提供了重要见解。这是少数在经过验证的功能残疾评分系统背景下研究一组基因重复患者临床病程的自然病史研究之一。本研究的独特之处在于它仅限于基因重复的受试者。该研究表明与其他描述PMD和其他PLP1相关疾病特征的研究有许多共性,但也为标志自然病史的不断发展的情况提供了重要的新见解。